Clinical trials: Meningioma, active
Meningioma
3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features
This prospective single-center study aims to evaluate the feasibility and clinical utility of three-dimensional magnetic resonance elastography (3D MRE) in assessing tumor stiffness and adhesion in patients with meningioma…
- Trial name
- NCT06955208
- Testing
- Magnetic Resonance Elastography, Intraoperative Assessment and Recording
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Meningioma
DOTATATE PET for Meningioma Radiation Planning
68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in…
- Trial name
- DOTATATE-RT (NCT06937268)
- Testing
- DOTATATE-PET scan
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- British Columbia Cancer Agency
Grade I Meningioma, Grade II Meningioma
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors.
- Conditions
- Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm
- Trial name
- HiPPI (NCT04278118)
- Testing
- Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Brain (Nervous System) Cancers, Glioblastoma
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level.
- Conditions
- Brain (Nervous System) Cancers, Glioblastoma, Glioma, Ependymoma
- Trial name
- EViDENCE-BT (NCT06804655)
- Testing
- Pharmacoscopy 1.0
- Where
- 3 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Brain Tumors
Diagnostic Performance and Quantitative Analysis of [18F]FET PET in Brain Tumours
This is a retrospective study encompassing all [18F]FET PET scans performed at our centre. By analysing both static and dynamic scans, conducting in-depth kinetic modelling, and comparing quantitative parameters across different…
- Trial name
- FET-BRAIN-DX (NCT07599917)
- Volunteers
- 69 people
- Sponsor
- IRCCS San Raffaele
Brain Cancer
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
The purpose of this study is to find out what effects, good or bad, the Optune device has on the patient and meningioma. This study is being done because currently there are no proven effective medical treatments for a…
- Trial name
- NCT01892397
- Testing
- Optune (NovoTTF-100A)
- Where
- 9 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Neoplasm, Brain Metastases
Cryoablation of Brain Neoplasm
This study will investigate the use of safety and feasibility of cryoablation in brain tumors
- Conditions
- Brain Neoplasm, Brain Metastases, Glioma, Meningioma
- Trial name
- NCT06753617
- Testing
- Cryoablation of brain neoplasm
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Erasmus Medical Center
Meningioma
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in…
- Trial name
- NCT06014905
- Testing
- Hyperpolarized carbon C 13 pyruvate, Magnetic Resonance Image (MRI), Saline
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Charlie Wang, MD, PhD
Grade 1 Meningioma, Grade 2 Meningioma
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation…
- Conditions
- Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
- Trial name
- NCT04082520
- Testing
- Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Intracranial Meningioma
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
- Trial name
- MOMENTUM-1 (NCT06955169)
- Testing
- [177Lu]Lu-DOTATATE, Standard of Care treatments
- Where
- 17 sites in United States
- Volunteers
- 130 people
- Sponsor
- RTOG Foundation, Inc.
Brain Metastases, Meningiomas
Measuring and Mapping Cognitive Decline After Brain Radiosurgery
Background Stereotactic Radiosurgery (SRS) is a localised radiotherapy treatment for patients with brain metastases or other benign tumours in the brain, like meningiomas.
- Conditions
- Brain Metastases, Meningiomas, Stereotactic Radiosurgery, Cognitive Decline
- Trial name
- CoDeB-Rad (NCT06466720)
- Testing
- Neurocognitive testing, Quality of Life questionnaire, Stereotactic radiosurgery
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Nottingham
CNS Tumors, Meningioma
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and including esthesioneuroblastoma, hemangioblastoma, medulloblastoma…
- Conditions
- CNS Tumors, Meningioma, Esthesioneuroblastoma, Hemangioblastoma
- Trial name
- DOMINO-START (NCT04081701)
- Testing
- Ga68-DOTATATE-PET/MRI
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Tumor, Brain, Meningioma of Brain
Intraoperative Brain Shift Calculation Study
The purpose of the study is to calculate magnitude, type of intraoperative brain shift and assess possibility of it's prediction.
- Conditions
- Tumor, Brain, Meningioma of Brain, Glioma, Metastasis Brain
- Trial name
- BRASH (NCT05477680)
- Testing
- Navigation-guided surgery
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Sklifosovsky Institute of Emergency Care
Grade 2 Meningioma, Grade 3 Meningioma
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
This phase I/II trial studies the side effects and best dose of nivolumab when given together with multi-fraction stereotactic radiosurgery and to see how well they work with or without ipilimumab in treating patients with grade…
- Conditions
- Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
- Trial name
- NCT03604978
- Testing
- Biospecimen Collection, Echocardiography Test, Ipilimumab
- Where
- 29 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Glial Tumor
Evaluation of the CONVIVO System
The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery.
- Conditions
- Glioblastoma, Glial Tumor, Brain Metastases, Meningioma
- Trial name
- NCT05139277
- Testing
- CONVIVO system, Conventional histologic evaluation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Low Grade Glioma, Malignant Brain Glioma
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor.
- Conditions
- Low Grade Glioma, Malignant Brain Glioma, Malignant Brain Neoplasm, Meningioma
- Trial name
- NCT06132685
- Testing
- Biospecimen Collection, Computed Tomography, Dexamethasone
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Emory University
Intracranial Meningioma, Recurrent Meningioma
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive).
- Conditions
- Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
- Trial name
- NCT02523014
- Testing
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib
- Where
- 791 sites in United States
- Volunteers
- 124 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neurofibromatosis Type 2, NF2
Selumetinib for NF2-Related Schwannomatosis
The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children…
- Conditions
- Neurofibromatosis Type 2, NF2, NF2-related Schwannomatosis, Meningioma
- Trial name
- ASSIST (NCT07707947)
- Testing
- Selumetinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Meningioma
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
This single arm, open-label study will evaluate the efficacy of Lutathera (177Lu-DOTATATE) administered intravenously every 8 weeks for a total of 4 doses in patients with progressive WHO I-III or residual high-risk Ga-DOTATATE…
- Trial name
- NCT03971461
- Testing
- Lutathera
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- NYU Langone Health
Malignant Meningioma
γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma
This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment…
- Trial name
- NCT07172178
- Testing
- γδ T-PD-1 Ab cells
- Volunteers
- 12 people
- Sponsor
- Nanjing Medical University